At the time of writing, Novo Nordisk ADR [NVO] stock is trading at $87.51, down -0.52%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVO shares have gain 11.21% over the last week, with a monthly amount drifted -1.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novo Nordisk ADR [NYSE: NVO] stock has seen the most recent analyst activity on January 06, 2025, when Bernstein upgraded its rating to a Mkt Perform. Previously, Goldman started tracking the stock with Buy rating on May 30, 2024, and set its price target to $156. On April 12, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $163 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $120 on January 23, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on December 01, 2023, and assigned it a price target of $120. In a note dated October 02, 2023, Argus initiated an Buy rating and provided a target price of $110 on this stock.
For the past year, the stock price of Novo Nordisk ADR fluctuated between $78.17 and $148.15. Currently, Wall Street analysts expect the stock to reach $158 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $87.51 at the most recent close of the market. An investor can expect a potential return of 80.55% based on the average NVO price forecast.
Analyzing the NVO fundamentals
According to Novo Nordisk ADR [NYSE:NVO], the company’s sales were 39.33B for trailing twelve months, which represents an 22.49% jump. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.44%, Pretax Profit Margin comes in at 0.44%, and Net Profit Margin reading is 0.35%. To continue investigating profitability, this company’s Return on Assets is posted at 0.24, Equity is 0.86 and Total Capital is 0.63. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 85.75 points at the first support level, and at 83.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 88.87, and for the 2nd resistance point, it is at 90.22.
Ratios To Look Out For
It is important to note that Novo Nordisk ADR [NYSE:NVO] has a current ratio of 0.94. In addition, the Quick Ratio stands at 0.75 and the Cash Ratio stands at 0.27. Considering the valuation of this stock, the price to sales ratio is 7.43, the price to book ratio is 16.19 and price to earnings (TTM) ratio is 28.38.
